2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1184

Response to Methotrexate and Glucocorticoid Injection in New Onset Arthritis after Checkpoint Inhibitor Therapy
Abstract Number: 1082

Responsiveness and Minimally Clinically Important Differences of Promis Measures in Rheumatoid Arthritis
Abstract Number: 1264

Responsiveness of Patient Reported Outcomes Measurement Information System (PROMIS®) Computerized Adaptive Tests (CATs) in Systemic Lupus Erythematosus (SLE)
Abstract Number: 2951

Responsiveness of the Patient Reported Outcomes Measurement Information System to Golimumab Intravenous and Infliximab Treatment in a Real World Clinical Trial in Rheumatoid Arthritis Patients
Abstract Number: 2668

Responsiveness of University of California Los Angeles Scleroderma Clinical Trial Consortium (GIT2.0) and Intestinal Visual Analogue Scale to Change in Systemic Sclerosis Patients
Abstract Number: 935

Results from a 52 Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis
Abstract Number: 42

Resveratrol Regulates Sirt1 to Control B Cells Activation and Plasma B Cells Differentiation
Abstract Number: 2478

Retention on Adalimumab, Etanercept, Golimumab and Infliximab in Two Eras – Experience of Patients with Rheumatoid Arthritis from a Real-World Database RHUMADATA®
Abstract Number: 2357

Retinal Vessel Morphological Associations with Systemic Inflammation and Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis
Abstract Number: 1330

Rhesus Theta Defensin 1 (RTD-1) Suppresses Disease-Associated Genes and Induces Anti-Inflammatory Expression Signature in Synovial Tissues of Rat Model of Rheumatoid Arthritis
Abstract Number: 277

Rheumatic Conditions Appearing De Novo after Infection with Chikungunya Virus in Venezuelan Patients
Abstract Number: 1173

Rheumatic Immune Related Adverse Events Due to Programmed Cell Death Protein 1 (PD-1) Inhibition for Cancer: Comprehensive Analysis of a Whole Cancer Cohort
Abstract Number: 1156

Rheumatic Immune Related Adverse Events from Checkpoint Inhibitor Therapy for Cancer: Long-Term Follow up Data
Abstract Number: 1153

Rheumatic Manifestations of Whim Syndrome
Abstract Number: 2422

Rheumatoid Arthritis (RA) Synovial Fluid Treg Cells Secrete IL-17 and at the Same Time Are Potent Suppressors of Tresp Cell Proliferation, TNF-α and Interferon γ Production

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].